BioSpace News Archive

AstraZeneca’s supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

Summit Therapeutics Inc. announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Theralase® Technologies Inc. (“Theralase®" or the “Company”) (TSXV:TLT)(OTCQB:TLTFF) is a clinical-stage pharmaceutical company dedicated to the research and development of light or radiation activated Photo Dynamic Compounds (“PDCs”) for the safe and effective destruction of various cancers, bacteria and viruses.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. that is developing ultra-high concentration nitric oxide as an immunotherapeutic for solid tumors, announced promising new preclinical data further supporting the company’s novel UNO therapy for various types of solid tumors as a single agent and in combination with checkpoint inhibitors.

Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced upcoming presentations from studies of CT1812, the Company’s lead candidate for the treatment of adults with early, mild and moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference being held October 24-27, 2023 virtually and in person in Boston, MA.

Theratechnologies Inc. announced that it has finalized all documentation giving effect to the amendments to certain of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time, with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager.

Nuvalent, Inc. announced that it has commenced an underwritten public offering of $300.0 million of its shares of Class A common stock.

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that the Company will deliver a corporate presentation at the upcoming ThinkEquity Conference.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the commercial launch of AspyreRx, the first cognitive behavioral therapy (CBT) app to receive U.S Food and Drug Administration (FDA) authorization as a Class II device to treat adults with type 2 diabetes (T2D).

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday.